874
Views
20
CrossRef citations to date
0
Altmetric
Psoriasis and dermatitis

Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity

, , , , , , , & show all
Pages 141-149 | Received 05 Feb 2018, Accepted 16 May 2018, Published online: 23 Jul 2018

References

  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516.
  • Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
  • Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med. 2014;47:37–45.
  • Wasilewska A, Winiarska M, Olszewska M, et al. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33:247–252.
  • Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Spec Pharm. 2004;10:318–325.
  • Armstrong AW, Koning JW, Rowse S, et al. Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States. Clin Drug Investig. 2017;37:493–501.
  • Goodfield M. Sequential use of biologics in moderate-to-severe plaque psoriasis: case studies illustrating an individualized approach. Br J Dermatol. 2012;167:21–26.
  • Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21:201–209.
  • Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13:848–853.
  • Brunasso AM, Puntoni M, Massone C. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol. 2012;166:447–449.
  • Khalid JM, Fox KM, Globe G, et al. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England. J Dermatolog Treat. 2014;25:67–72.
  • Iskandar IYK, Ashcroft DM, Warren RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2017;176:1297–1307.
  • Eichler GS, Cochin E, Han J, et al. Exploring Concordance of Patient-Reported Information on PatientsLikeMe and Medical Claims Data at the Patient Level. J Med Internet Res. 2016;18:e110.
  • Risson V, Ghodge B, Bonzani IC, et al. Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis. J Med Internet Res. 2016;18:e249.
  • Ober NS, Grubmuller J, Farrell M, et al. System and method for generating de-identified health care data. Google Patents. 2004.
  • Zubeldia K, Romney GW. Anonymously linking a plurality of data records. Google Patents. 2002.
  • Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
  • Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51:S11–S21.
  • Warren RB, Smith CH, Yiu ZZN, et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.